However, patients in the low-infiltration groups of CD8 + T cells could also show benefit under IO/TKI treatment, compared with TKI monotherapy (low CD8 + T cells in tumor center, HR = 0.73, P = 0.039; low CD8 + T cells in total area, HR = 0.72, P = 0.033; low CD8 + T cells by CIBERSORT, HR = 0.73, P = 0.033; Fig. 2A). Here, CD8A is linked to neoplasm.